Teleflex (NYSE:TFX) Earns “Neutral” Rating from Piper Sandler

Piper Sandler reaffirmed their neutral rating on shares of Teleflex (NYSE:TFX) in a report released on Friday, Marketbeat.com reports. The firm currently has a $140.00 target price on the medical technology company’s stock, down from their previous target price of $255.00.

A number of other equities analysts also recently commented on TFX. Royal Bank of Canada dropped their price objective on Teleflex from $275.00 to $245.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Mizuho lowered their price target on Teleflex from $275.00 to $250.00 and set a “neutral” rating on the stock in a report on Friday, November 1st. Citizens Jmp downgraded Teleflex from an “outperform” rating to a “market perform” rating in a report on Thursday. Needham & Company LLC reiterated a “hold” rating on shares of Teleflex in a report on Monday, December 16th. Finally, StockNews.com upgraded Teleflex from a “hold” rating to a “buy” rating in a report on Thursday, November 28th. Nine equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, Teleflex has a consensus rating of “Hold” and a consensus price target of $196.83.

Teleflex Trading Down 4.7 %

NYSE:TFX opened at $132.58 on Friday. The stock’s 50 day moving average price is $175.44 and its 200 day moving average price is $205.04. Teleflex has a 52 week low of $130.60 and a 52 week high of $249.90. The company has a market capitalization of $6.16 billion, a P/E ratio of 26.36, a P/E/G ratio of 1.73 and a beta of 1.16. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.39 and a current ratio of 2.42.

Teleflex (NYSE:TFX) last released its quarterly earnings data on Thursday, February 27th. The medical technology company reported $3.89 EPS for the quarter, topping analysts’ consensus estimates of $3.86 by $0.03. Teleflex had a return on equity of 14.19% and a net margin of 7.85%. The firm had revenue of $795.40 million for the quarter, compared to the consensus estimate of $813.24 million. On average, research analysts forecast that Teleflex will post 13.98 EPS for the current fiscal year.

Teleflex Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 17th. Stockholders of record on Friday, March 7th will be given a $0.34 dividend. The ex-dividend date of this dividend is Friday, March 7th. This represents a $1.36 annualized dividend and a dividend yield of 1.03%. Teleflex’s dividend payout ratio is 27.04%.

Institutional Investors Weigh In On Teleflex

Hedge funds have recently modified their holdings of the business. Vontobel Holding Ltd. boosted its position in shares of Teleflex by 21.9% in the fourth quarter. Vontobel Holding Ltd. now owns 1,393 shares of the medical technology company’s stock valued at $248,000 after acquiring an additional 250 shares during the period. Simplify Asset Management Inc. bought a new stake in shares of Teleflex in the third quarter valued at approximately $4,800,000. JPMorgan Chase & Co. lifted its position in Teleflex by 14.3% in the third quarter. JPMorgan Chase & Co. now owns 155,158 shares of the medical technology company’s stock worth $38,374,000 after purchasing an additional 19,466 shares during the period. Sumitomo Mitsui Trust Group Inc. lifted its position in Teleflex by 5.2% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 108,231 shares of the medical technology company’s stock worth $19,263,000 after purchasing an additional 5,322 shares during the period. Finally, Lecap Asset Management Ltd. bought a new position in Teleflex in the fourth quarter worth $729,000. 95.62% of the stock is owned by institutional investors.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.